Please login to the form below

Not currently logged in
Email:
Password:

Asana appoints new chief medical officer

Louis Denis joins from Boehringer Ingelheim

Asana Biosciences has appointed Louis Denis as its new chief medical officer.

Denis is a medical oncologist with over 20 years of academic and industry experience in clinical cancer drug development.

He will be responsible for the overall strategic direction and medical oversight of clinical development of Asana's novel product candidates.

He said: “I am delighted to join Asana at this transformative time for the company.

“I look forward to working with the Asana team and its scientific advisory board to advance the company's broad portfolio of differentiated targeted therapies to help address major unmet medical needs.”

Denis has formerly held strategic and leadership positions at Boehringer-Ingelheim, where he headed the medical team, and Pfizer. 

Sandeep Gupta, president and chief executive officer of Asana Biosciences, said: “We are extremely pleased with the addition of Dr. Denis, a highly experienced physician and scientist, to our team. It represents a significant step in our evolution as an oncology-focused clinical development company.”

29th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...